About this trial
In hindsight, the first "face graft" raises the fundamental problem of composite tissue allotransplantation (hand, larynx, abdominal wall, etc.) with the addition of specific technical and philosophical problems.
By proposing a prospective study concerning five new patients over the next three years, in the light of this first experience, the authors would like to confirm the surgical feasibility of this type of procedure, possibly extending it to other parts of the face (lateral third) and, like English and American teams, considering the possibility of total facial surface reconstruction.
In parallel, and while complying with the usual immunosuppression procedures, the deliberate choice of creating a microchimerism by the infusion of bone marrow stem cells (the origin and quantity of which will need to be determined) will be reaffirmed, in order to improve mucocutaneous tissue tolerance, while confirming the safety of this type of approach.
Five new cases will also provide observations for the many new fields of research developing around composite tissue transplants (neurophysiology, skin histopathology, psychiatry, haematology, immunology, etc.).
Eligibility criteria
Qualifiers
Patients with loss of unrepairable substance by conventional techniques shreds, at the front
Disqualifiers
Facial lesions repaired by conventional reconstructive surgery techniques
History of malignancy in remission for less than 5 years
Malignant neoplasm undergoing changes
Severe psychiatric history
Trial design
Treatments tested in this trial
- composite tissue allotransplantation